scholarly article | Q13442814 |
review article | Q7318358 |
P50 | author | Ana Martínez | Q30506374 |
Carmen Gil | Q45286654 | ||
Daniel I Pérez | Q56250319 | ||
P2860 | cites work | The blood-brain barrier: bottleneck in brain drug development | Q22336985 |
Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme | Q24291728 | ||
Modeling of a human circadian mutation yields insights into clock regulation by PER2 | Q24292897 | ||
Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease | Q24308731 | ||
The protein kinase complement of the human genome | Q24324497 | ||
Dopamine covalently modifies and functionally inactivates parkin | Q24338423 | ||
The effects of connexin phosphorylation on gap junctional communication | Q24603834 | ||
Setting clock speed in mammals: the CK1 epsilon tau mutation in mice accelerates circadian pacemakers by selectively destabilizing PERIOD proteins | Q24629727 | ||
The selectivity of protein kinase inhibitors: a further update | Q24654622 | ||
Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent | Q27621242 | ||
Crystal structure of a conformation-selective casein kinase-1 inhibitor | Q27622090 | ||
The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2 | Q27625243 | ||
Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole | Q27635437 | ||
Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insight | Q27639922 | ||
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA) | Q27641451 | ||
The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules | Q27649904 | ||
Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2 | Q27655439 | ||
Casein kinase I-like protein kinases encoded by YCK1 and YCK2 are required for yeast morphogenesis | Q27932715 | ||
Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein | Q28141645 | ||
Casein kinase II-mediated phosphorylation regulates alpha-synuclein/synphilin-1 interaction and inclusion body formation | Q28188133 | ||
Casein kinase I: another cog in the circadian clockworks | Q28209277 | ||
The casein kinase 1 family: participation in multiple cellular processes in eukaryotes | Q28235956 | ||
Synaptic transmission block by presynaptic injection of oligomeric amyloid beta | Q28238942 | ||
Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta | Q28239322 | ||
S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function | Q28258212 | ||
Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis | Q28261784 | ||
Regulation of Alzheimer's disease amyloid-beta formation by casein kinase I | Q28577875 | ||
An inhibitor of casein kinase I epsilon induces phase delays in circadian rhythms under free-running and entrained conditions | Q28578516 | ||
Polyhalogenobenzimidazoles: synthesis and their inhibitory activity against casein kinases | Q28581363 | ||
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism | Q29547302 | ||
Targeting cancer with small molecule kinase inhibitors | Q29547395 | ||
Protein kinases--the major drug targets of the twenty-first century? | Q29615339 | ||
One-thousand-and-one substrates of protein kinase CK2? | Q29615345 | ||
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis | Q29615597 | ||
Parkinson's disease | Q29616302 | ||
Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity | Q30448692 | ||
Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum. | Q30913371 | ||
Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study | Q31117999 | ||
Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2). | Q33207638 | ||
p53-dependent inhibition of mammalian cell survival by a genetically selected peptide aptamer that targets the regulatory subunit of protein kinase CK2. | Q33245656 | ||
Expanding the chemical diversity of CK2 inhibitors. | Q33344802 | ||
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo | Q33346339 | ||
The selectivity of inhibitors of protein kinase CK2: an update | Q33347545 | ||
Purification of casein kinase I and isolation of cDNAs encoding multiple casein kinase I-like enzymes | Q33451141 | ||
Targeting protein kinases in central nervous system disorders | Q33671660 | ||
Casein kinase 2 as a potentially important enzyme in the nervous system | Q33829605 | ||
Identification of inhibitory autophosphorylation sites in casein kinase I epsilon | Q33878515 | ||
Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein | Q34091623 | ||
Role of COOH-terminal Phosphorylation in the Regulation of Casein Kinase Iδ | Q34304545 | ||
p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugs | Q34444295 | ||
A new molecular link between the fibrillar and granulovacuolar lesions of Alzheimer's disease | Q34505264 | ||
Toward the rational design of protein kinase casein kinase-2 inhibitors | Q34792890 | ||
A role for casein kinase 1 epsilon in the locomotor stimulant response to methamphetamine. | Q34892958 | ||
Protein kinase CK2: structure, regulation and role in cellular decisions of life and death | Q34978734 | ||
Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period | Q34982171 | ||
MAPKs: new targets for neurodegeneration | Q35095136 | ||
Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials | Q35155745 | ||
Protein kinase CK2 in health and disease: CK2: a key player in cancer biology | Q35270830 | ||
Rho kinase, a promising drug target for neurological disorders | Q36111908 | ||
The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer development | Q36269124 | ||
Features and potentials of ATP-site directed CK2 inhibitors | Q36273845 | ||
Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: evaluation of their effects on cells and different molecular forms of human CK2. | Q36276160 | ||
CKI, there's more than one: casein kinase I family members in Wnt and Hedgehog signaling | Q36397808 | ||
Tau therapeutic strategies for the treatment of Alzheimer's disease | Q36483103 | ||
Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). | Q43601491 | ||
Anti-AIDS agents. 46. Anti-HIV activity of harman, an anti-HIV principle from Symplocos setchuensis, and its derivatives | Q43688171 | ||
Protein kinase CK2: a newcomer in the 'druggable kinome'. | Q44016530 | ||
Ribofuranosyl-benzimidazole derivatives as inhibitors of casein kinase-2 and casein kinase-1. | Q44316862 | ||
Characterization of (-)-matairesinol as a potent inhibitor of casein kinase I in vitro | Q44337455 | ||
Aberrant casein kinase II in Alzheimer's disease | Q44378382 | ||
Selectivity of 4,5,6,7-tetrabromobenzimidazole as an ATP-competitive potent inhibitor of protein kinase CK2 from various sources. | Q44466447 | ||
Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking | Q44474542 | ||
Casein kinase II is associated with neurofibrillary tangles but is not an intrinsic component of paired helical filaments | Q44664318 | ||
2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. | Q45052212 | ||
Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole | Q45164317 | ||
Inclining the purine base binding plane in protein kinase CK2 by exchanging the flanking side-chains generates a preference for ATP as a cosubstrate. | Q45290258 | ||
Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). | Q45713586 | ||
Identification of casein kinase-1 phosphorylation sites on TDP-43. | Q46088509 | ||
Autophosphorylation of carboxy-terminal residues inhibits the activity of protein kinase CK1alpha | Q46179780 | ||
Identification of novel protein kinase CK1 delta (CK1delta) inhibitors through structure-based virtual screening | Q46361622 | ||
Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2. | Q46478098 | ||
Protein kinase CK2 modulates synaptic plasticity by modification of synaptic NMDA receptors in the hippocampus | Q46593528 | ||
Physiological role for casein kinase 1 in glutamatergic synaptic transmission. | Q46598656 | ||
Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function | Q46797053 | ||
Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo | Q46802179 | ||
Casein kinase I transduces Wnt signals | Q47069139 | ||
Neurotrophin-induced activation of casein kinase 2 in rat hippocampal slices | Q47734681 | ||
Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis | Q48139089 | ||
Different expression patterns of CK2 subunits in the brains of experimental animals and patients with transmissible spongiform encephalopathies | Q48437741 | ||
Identifying interaction motifs in CK2beta--a ubiquitous kinase regulatory subunit | Q48545932 | ||
Casein kinase-1 isoforms differentially associate with neurofibrillary and granulovacuolar degeneration lesions | Q48606594 | ||
Phosphorylation of apolipoprotein-E at an atypical protein kinase CK2 PSD/E site in vitro | Q48895043 | ||
Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. | Q48965240 | ||
Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. | Q51028667 | ||
Inhibition of casein kinase I epsilon/delta produces phase shifts in the circadian rhythms of Cynomolgus monkeys. | Q51773887 | ||
Amyloid beta-protein stimulates casein kinase I and casein kinase II activities. | Q52221605 | ||
Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. | Q52575181 | ||
Identification of chemical inhibitors of protein-kinase CK2 subunit interaction. | Q52587478 | ||
Casein kinase 1 delta mRNA is upregulated in Alzheimer disease brain. | Q53234938 | ||
Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases. | Q53236807 | ||
Glycogen synthase kinase 3 phosphorylation of different residues in the presence of different factors: analysis on tau protein. | Q53856938 | ||
Synthesis and kinase inhibitory activity of novel substituted indigoids. | Q54727713 | ||
Disease-associated casein kinase I delta mutation may promote adenomatous polyps formation via a Wnt/beta-catenin independent mechanism. | Q55042756 | ||
Protein kinase CK2 links extracellular growth factor signaling with the control of p27Kip1 stability in the heart | Q56973092 | ||
Mass Spectrometry Analysis of a Protein Kinase CK2β Subunit Interactome Isolated from Mouse Brain by Affinity Chromatography | Q58037526 | ||
Circadian rhythms in the CNS and peripheral clock disorders: human sleep disorders and clock genes | Q36735272 | ||
Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest | Q36787138 | ||
CK2beta gene silencing increases cell susceptibility to influenza A virus infection resulting in accelerated virus entry and higher viral protein content | Q36808656 | ||
JNK signalling: a possible target to prevent neurodegeneration. | Q36855703 | ||
Hemoglobin neurotoxicity is attenuated by inhibitors of the protein kinase CK2 independent of heme oxygenase activity | Q36915740 | ||
Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. | Q36968720 | ||
Tumorigenesis and neurodegeneration: two sides of the same coin? | Q37214823 | ||
A structural insight into CK2 inhibition | Q37216422 | ||
Protein kinase CK2 in human diseases. | Q37239690 | ||
Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders | Q37249765 | ||
ATP-noncompetitive inhibitors of CDK-cyclin complexes. | Q37336692 | ||
Casein Kinase I epsilon positively regulates the Akt pathway in breast cancer cell lines | Q37390974 | ||
New protein kinase CK2 inhibitors: jumping out of the catalytic box. | Q37402052 | ||
Protein kinase inhibitors: contributions from structure to clinical compounds | Q37417742 | ||
Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review | Q37418238 | ||
Protein kinase CK2 in health and disease: Protein kinase CK2: from structures to insights. | Q37456255 | ||
Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction | Q38299025 | ||
The regulatory beta subunit of protein kinase CK2 mediates formation of tetrameric CK2 complexes | Q38315495 | ||
3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta. | Q39826704 | ||
Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. | Q39951176 | ||
Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice. | Q40082517 | ||
D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. | Q40098388 | ||
Development and exploitation of CK2 inhibitors | Q40342605 | ||
Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy | Q40503541 | ||
Casein kinase 1 delta phosphorylates tau and disrupts its binding to microtubules | Q40592760 | ||
RING finger 1 mutations in Parkin produce altered localization of the protein | Q40629977 | ||
Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype | Q40817463 | ||
Anticancer alkaloid lamellarins inhibit protein kinases | Q41905449 | ||
Casein kinase II contributes to the synergistic effects of BMP7 and BDNF on Smad 1/5/8 phosphorylation in septal neurons under hypoglycemic stress | Q41912514 | ||
Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2. | Q43277656 | ||
P433 | issue | 6 | |
P921 | main subject | neurodegeneration | Q1755122 |
PF-4800567 | Q7119049 | ||
P304 | page(s) | 924-954 | |
P577 | publication date | 2010-06-23 | |
P1433 | published in | Medicinal Research Reviews | Q2436033 |
P1476 | title | Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases | |
P478 | volume | 31 |
Q52656620 | 1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders. |
Q27677250 | 2-Benzamido-N-(1H-benzo[d]imidazol-2-yl)thiazole-4-carboxamide derivatives as potent inhibitors of CK1δ/ε |
Q64788264 | A Triazolotriazine-Based Dual GSK-3β/CK-1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition |
Q33559650 | Alleviation of behavioral hypersensitivity in mouse models of inflammatory pain with two structurally different casein kinase 1 (CK1) inhibitors |
Q52654990 | Atlas stumbled: kinesin light chain-1 variant E triggers a vicious cycle of axonal transport disruption and amyloid-β generation in Alzheimer's disease. |
Q33736687 | Bioactive marine drugs and marine biomaterials for brain diseases |
Q60897585 | Biological and Pharmacological Characterization of Benzothiazole-Based CK-1δ Inhibitors in Models of Parkinson's Disease |
Q38828117 | CK1δ activity is modulated by CDK2/E- and CDK5/p35-mediated phosphorylation |
Q42204673 | CK1δ in lymphoma: gene expression and mutation analyses and validation of CK1δ kinase activity for therapeutic application |
Q54109929 | CK2 Phosphorylating I2PP2A/SET Mediates Tau Pathology and Cognitive Impairment. |
Q39076762 | CK2-An Emerging Target for Neurological and Psychiatric Disorders |
Q38211598 | Casein kinase: the triple meaning of a misnomer |
Q38632634 | Casein kinases as potential therapeutic targets |
Q34127839 | Circadian gene variants in cancer. |
Q36798054 | Crosstalk between casein kinase II and Ste20-related kinase Nak1. |
Q93166659 | Discovering New Casein Kinase 1d Inhibitors with an Innovative Molecular Dynamics Enabled Virtual Screening Workflow |
Q34891066 | Dopaminergic pathway polymorphisms and heroin addiction: further support for association of CSNK1E variants |
Q42481944 | Effects of CK2 inhibition in cultured fibroblasts from Type 1 Diabetic patients with or without nephropathy |
Q38303007 | Effects of altered expression and activity levels of CK1δ and ɛ on tumor growth and survival of colorectal cancer patients |
Q28482403 | Exploiting the MDM2-CK1α protein-protein interface to develop novel biologics that induce UBL-kinase-modification and inhibit cell growth |
Q40189553 | Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis |
Q39357662 | FAF1 mediates regulated necrosis through PARP1 activation upon oxidative stress leading to dopaminergic neurodegeneration |
Q26865707 | Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder |
Q34591684 | Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease |
Q27930417 | Hrr25/CK1δ-directed release of Ltv1 from pre-40S ribosomes is necessary for ribosome assembly and cell growth |
Q30454128 | Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors |
Q36433202 | Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer's disease pathology. |
Q36063680 | Interaction of CK1δ with γTuSC ensures proper microtubule assembly and spindle positioning |
Q36268711 | Novel group-based QSAR and combinatorial design of CK-1δ inhibitors as neuroprotective agents |
Q98563342 | Ozone: a natural bioactive molecule with antioxidant property as potential new strategy in aging and in neurodegenerative disorders |
Q33797449 | Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis |
Q30574827 | Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis |
Q37247661 | Protein kinase CK2 governs the molecular decision between encephalitogenic TH17 cell and Treg cell development. |
Q38815398 | Protein kinase CK2 regulates metal toxicity in neuronal cells |
Q90378129 | Recapitulation of Pathological TDP-43 Features in Immortalized Lymphocytes from Sporadic ALS Patients |
Q34333403 | SNP-PRAGE: SNP-based parametric robust analysis of gene set enrichment |
Q47884524 | Several human cyclin-dependent kinase inhibitors, structurally related to roscovitine, are new anti-malarial agents. |
Q27682893 | Structure of the kinase domain of Gilgamesh fromDrosophila melanogaster |
Q36855812 | Targeting TDP-43 phosphorylation by Casein Kinase-1δ inhibitors: a novel strategy for the treatment of frontotemporal dementia. |
Q21129297 | The CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis |
Q54978506 | The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms. |
Q28077409 | The New Role for an Old Kinase: Protein Kinase CK2 Regulates Metal Ion Transport |
Q36237271 | The Selectivity of CK2 Inhibitor Quinalizarin: A Reevaluation |
Q28293759 | The casein kinase 2-nrf1 axis controls the clearance of ubiquitinated proteins by regulating proteasome gene expression |
Q91866908 | Therapeutic Potential of the Hsp90/Cdc37 Interaction in Neurodegenerative Diseases |
Q37374036 | Transcriptome analysis of HIV-infected peripheral blood monocytes: gene transcripts and networks associated with neurocognitive functioning |
Q35526322 | Unbiased functional proteomics strategy for protein kinase inhibitor validation and identification of bona fide protein kinase substrates: application to identification of EEF1D as a substrate for CK2. |
Search more.